Third ADC with Synaffix’s Technology Enters Clinical Development

AMSTERDAM, NETHERLANDS, September 29, 2021 — Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announces that its...

BGV Expands Team with the Appointment of a Partner and Venture Partner

Naarden, The Netherlands, 14 September 2021 – BioGeneration Ventures (“BGV”), a leading early-stage VC in European biopharma, today announces the appointment of Keno Gutierrez as Partner, and Wouter Verhoeven as Venture Partner. Collectively these two appointments...

Kyowa Kirin Taps Synaffix ADC Technology to Expand Its Pipeline

Synaffix will provide all necessary proprietary ADC technologies, including GlycoConnect™, HydraSpace™, and select toxSYN™ linker-payloads Kyowa Kirin will leverage its innovative antibody-based therapeutics pipeline to develop a portfolio of ADCs with optimized...